Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | Journal of Translational Medicine

Fig. 4

From: HIF-1α inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect

Fig. 4

HIF-1α inhibitor echinomycin preserves GVL effect and improved leukemia-free survival. Lethally irradiated Balb/c mice were infused with A20 leukemia cells plus syngeneic or allogeneic bone marrow cells and splenic T cells from Balb/c (syn-HSCT) or C57BL/6 (allo-HSCT) mice. Mice were treated with vehicle or echinomycin, and observed daily through day 70 post HSCT. Survival of animals is shown. ***P < 0.001, allo-HSCT + A20 echinomycin vs syn-HSCT + A20 echinomycin; **P < 0.01, allo-HSCT + A20 echinomycin vs allo-HSCT + A20 vehicle. Data are representatives of two independent experiments with n = 8–11 per group

Back to article page